Wei Zhou,Tao Han,Zhaozhe Liu,Xiaodan Yang,Yu Liu,Wei Wang,Benqiang Yang,Xiaodong Xie. The efficacy of Kanglaite injection during treatment with tyrosine kinase inhibitor in elderly patients with non-small cell lung cancer. Oncol Transl Med, 2017, 3: 99-102.
The efficacy of Kanglaite injection during treatment with tyrosine kinase inhibitor in elderly patients with non-small cell lung cancer
Received:November 28, 2016  Revised:June 05, 2017
View Full Text  View/Add Comment  Download reader
KeyWord:non-small cell lung cancer (NSCLC); Kanglaite injection (KLT); epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI)
Author NameAffiliationE-mail
Wei Zhou Department of Diagnostic radiology, The General Hospital of Shenyang Military Region, Shenyang 110016, China 1531279822@qq.com 
Tao Han Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China  
Zhaozhe Liu Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China  
Xiaodan Yang Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China  
Yu Liu Department of Diagnostic radiology, The General Hospital of Shenyang Military Region, Shenyang 110016, China  
Wei Wang Department of Diagnostic radiology, The General Hospital of Shenyang Military Region, Shenyang 110016, China  
Benqiang Yang Department of Diagnostic radiology, The General Hospital of Shenyang Military Region, Shenyang 110016, China crzs281@tom.com 
Xiaodong Xie Department of Oncology, General Hospital of Shenyang Military Region, Shenyang 110016, China doctor_xxd@163.com 
Hits: 5906
Download times: 7299
Abstract:
      Objective?Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs) are widely used in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients. The Kanglaite injection (KLT) is a novel broad-spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (coix seed). After its approval in 1995, KLT has become the most popular anti-cancer drug in China. As of this writing, no standard treatment guideline is available for elder patients with NSCLC, and the role of traditional Chinese medicinal herbs, including KLT, combined with TKI treatment remains unknown. This retrospective study evaluated the efficacy and safety of KLT in elderly NSCLC patients during TKI treatment. Methods?Thirty elderly patients aged 71-79 years with histopathologically confirmed NSCLC attending the General Hospital of the Shenyang Military Region were enrolled in the study and received EGFR-TKI treatment. All participants received 200 mL KLT injections at the same time on days 1–21. Erlotinib (150 mg) or gefitinib (250 mg) was administered daily from days 1 to 21, and the cycle was repeated every 21 days. The endpoint of the primary study was the disease control rate. Results?Thirty elderly patients were enrolled in this study. The objective response rate was 21.3% [95% confidence interval (CI): 8.6% to 35.2%], whereas the disease control rate was 80.4% (95% CI: 71.8% to 97.0%). The grade 3 or 4 adverse effects included leucopenia (13.7%), neutropenia (13.4%), anemia (2.9%), and nausea or vomiting (2.7%). Conclusion?The administration of KLT combined with erlotinib or gefitinib showed high efficacy in elderly NSCLC patients. The adverse effects of the drug combination were well tolerated by the patients. KLT combined with TKI treatment might provide a satisfactory therapeutic strategy for elderly NSCLC patients.
Close